# Table of Contents

## Highlights of This Issue 1973

### SPECIAL FEATURES

#### CCR 20th Anniversary Commentary

- **1975** CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come  
  Sami I. Bashour and Nuhad K. Ibrahim

#### CCR Translations

- **1978** PLEKH5: A Key to Unlock the Blood–Brain Barrier?  
  Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos  
  See related article, p. 2138

#### CCR New Strategies

- **1984** New Strategies in Glioblastoma: Exploiting the New Biology  
  Howard A. Fine

#### Molecular Pathways

- **1989** Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer  
  Lynnette Fernandez-Cuesta and Roman K. Thomas

- **1995** Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy  
  Alexander Lin and Amit Maity

#### Reviews

- **2001** Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?  
  Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

## 2009 Genomic Landscape of Human Papillomavirus–Associated Cancers  
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

### CANCER THERAPY: CLINICAL

- **2020** Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia  

  See related commentary, p. 1981

### PERSONALIZED MEDICINE AND IMAGING

- **2029** Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial  
  Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, J. Winder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chiu, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Aghani, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGi) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

- **2038** Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy  
  Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiader

- **2045** Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia  
  Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamla Saiya-Cork, Kerby Shedden, and Sami N. Malek
2057 MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller, Ghazaleh Tabatabai, Barbel Kastner, Jorg Fehberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Plattner, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homiczko, Josef Pichler, Guido Nißkhal, Jürgen Meixensberger, Peter Vajkoczy, Spyros Koliáss, Johannes Hising, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group

2065 PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

2067 Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Jasdeep K. Saggar and Ian F. Tannock

2077 Targeted Ax1 Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

2078 Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen, Marcus M. Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R. Henner, Rene Meinzer, Aaron Sato, Jalpa Shah, Tracy Tang, Breanna Gurney, Min Wang, Chun Zhang, Ann M. Kapoun, John Lewicki, Austin Gurney, and Timothy Hoey

2097 Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellosoillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Luca Lazzarì, Noelia Fernàz, Mariangela Russo, Sandra Misale, Iria González, Mar Iglesias, Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Cirafulli, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquín Bellmunt, Gianni De Fabritius, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut
Table of Contents

2167 IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177 Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Comelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

LETTERS TO THE EDITOR

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION

2189 Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190 Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192 Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.